Researchers from The University of Texas MD Anderson Cancer Center found specific intestinal microbiota signatures correlate with high-grade adverse events and response to combined CTLA-4 and PD-1 blockade treatment. The ...
Jul 8, 2021
0
8
A high rate of genetic mutations within a tumor, known as high tumor mutation burden (TMB), was only useful for predicting clinical responses to immune checkpoint inhibitors in a subset of cancer types, according to a new ...
Mar 15, 2021
1
28
A new study from researchers at the UCLA Jonsson Comprehensive Cancer Center helps explain how disruptions in genes can lead to the resistance to one of the leading immunotherapies, PD-1 blockade, and how new drug combinations ...
May 28, 2020
0
1
A small molecule that inhibits energy production in immune T-cells allows some tumours to escape treatment with an immunotherapy called PD-1 blockade therapy, says a study in mice published today in eLife.
Mar 3, 2020
0
4
The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within specialized immune-cell clusters known as tertiary lymphoid structures (TLS), according to researchers ...
Jan 15, 2020
0
297
Mount Sinai researchers have developed a way to use immunotherapy drugs against treatment-resistant non-Hodgkin's lymphomas for the first time by combining them with stem cell transplantation, an approach that also dramatically ...
Aug 2, 2019
0
1
A team of researchers affiliated with Johns Hopkins University and Memorial Sloan Kettering Cancer Center has found some of the reasons for different responses to anti-PD-1 checkpoint blockade immunotherapy in cancer patients. ...
A collaborative experimental study led by researchers at Cima and Clinica Universidad de Navarra proposes a new therapeutic approach against cancer that dissociates efficacy and toxicity in the use of combined immunotherapy ...
May 3, 2019
0
197
Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body.
Apr 8, 2019
1
1735
A Ludwig Cancer Research study has uncovered a cellular mechanism by which melanomas that fail to respond to checkpoint blockade may be made susceptible to immunotherapies. Led by Ping-Chih Ho of the Lausanne Branch of the ...
Jan 23, 2019
0
2
